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Abstract The use of bisindolylmaleimide derivatives of staur-
osporine as selective inhibitors of protein kinase C (PKC) is in 
doubt following the report by Alessi [FEBS Lett. 402 (1997) 
121-123] that Ro31-8220 and GF109203X are potent in vitro 
inhibitors of p70 S6 kinase and mitogen-activated protein kinase-
activated protein kinase-Iß, as well as of PKC. Here we show 
that the phorbol ester-stimulated release of choline- and 
ethanolamine-metabolites from C6 glioma cells due to phospho-
lipid hydrolysis by phospholipase D (PLD) is not inhibited by 
rapamycin or PD98059, specific inhibitors respectively of p70 S6 
kinase and MAPKK (MEK) and thus of MAPKAP kinase-lß 
but is still completely blocked by Ro31-8220. We conclude 
therefore that p70S6k and MAPKAP kinase-lß as well as 
MAPK are not involved in signalling pathways downstream of 
PKC that regulate phorbol ester-stimulated phospholipid turn-
over and that the inhibitory action of Ro31-8220 occurs by 
blocking PKC which regulates at least one pathway to PLD 
activation. The PI-3 kinase inhibitor, wortmannin, inhibits the 
phorbol ester-stimulated release of ethanolamine- but not cho-
line-metabolites from C6 cells suggesting that different PLD 
isoforms regulate the turnover of PtdEth and PtdCho in C6 cells. 
Both PLD isoforms are activated via PKC but the PtdEth-PLD 
is also regulated via a wortmannin-sensitive pathway. 
© 1997 Federation of European Biochemical Societies. 
1. Introduction 
The microbial metabolite, staurosporine, was used in the 
past as a specific inhibitor of protein kinase C (PKC). How-
ever, due to its competitive inhibition of the ATP-binding site, 
it is now known to be a potent but rather unselective inhibitor 
of several serine/threonine and tyrosine kinases [1]. Various 
bisindolylmaleimide derivatives of staurosporine show an im-
proved selectivity for inhibition of protein kinase C (PKC) 
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compared with some other kinases while retaining the potency 
of staurosporine [2,3]. Ro31-8220, for example, has an IC5o of 
23 nM for inhibition of rat brain PKC in vitro compared with 
1.5 uM and 17 uM for PKA and Ca2+/calmodulin-dependent 
protein kinase respectively [3]. Ro31-8220 does not show sig-
nificant PKC subspecies specificity [3] but has been widely 
used to investigate the involvement of PKC in cell signalling 
pathways (e.g. [4,5,9]). 
Conclusions about PKC based on the use of bisindolylma-
leimides are now in doubt following the recent report from 
Alessi [6] that Ro31-8220 and GF109203X are potent inhib-
itors in vitro of p70 S6 kinase (p70S6k) and MAP kinase-acti-
vated protein (MAPKAP) kinase-lß, in addition to PKC. 
This finding makes it necessary, when using Ro31-8220 and 
similar compounds to establish a role for PKC in signalling 
pathways, to eliminate an involvement of p70S6k and MAP-
KAP kinase-lß. We [7,8] have used Ro31-8220 to define a role 
for PKC in the phorbol ester-stimulated turnover of phospha-
tidylcholine (PtdCho) and Eth-containing phospholipids 
(PtdEth) in C6 glioma cells by phospholipase D (PLD), as 
have others in different cell lines (e.g. [4,9]). Ro31-8220 com-
pletely blocks the phorbol ester-stimulated release of choline-
lipid headgroup metabolites to the extracellular medium [7,8], 
a finding taken previously to indicate an involvement of PKC 
but which from Alessi's report [6] may also indicate a role for 
p70S6k and/or MAPKAP kinase-lß. Here we show that phor-
bol ester-stimulated Cho- and Eth- metabolite release from C6 
cells is not affected by rapamycin which inhibits p70S6k or by 
PD98059 which inhibits MAPKK and thus prevents activa-
tion of MAPKAP kinase-lß [6] while Ro31-8220 is still inhib-
itory. The results show that neither p70S6k nor MAPKAP 
kinase-lß function downstream of PKC to activate PLD 
and confirm the previous view that phorbol ester-stimulated 
turnover of PtdCho and PtdEtn is mediated, at least partially, 
through PKC [7,8]. 
2. Materials and methods 
2.1. Materials 
C6 glioma cells were obtained from the European Collection of 
Animal Cell Cultures (Portón Down, England). Cell culture plastic 
was from Corning (Bibby-Sterilin, Stone, England). Trypsin/EDTA 
(10 X) and DMEM were from Life Technologies (Paisley, Scotland). 
FBS and staurosporine were from Sigma (Poole, Dorset, England). 
Ro31-8220 was a gift from Dr. G. Lawton, Roche Research Centre, 
Welwyn, England. Rapamycin and wortmannin were from LC Labo-
ratories (Alexis Corp., Nottingham, England). PD98059 was a gift 
from Professor P. Cohen (University of Dundee). [3H]choline and 
[3H]ethanolamine or [14C]ethanolamine were from Amersham (Little 
Chalfont, Bucks., England). 12-0-tetradecanoylphorbol 13-acetate 
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Fig. 1. Action of the phorbol ester TPA and the bisindolylmalei-
mide Ro31-8220 on: A, choline- and, B, ethanolamine-metabolite 
release to the extracellular medium from C6 glioma cells. Cells were 
labelled to equilibrium as described and treated for the time periods 
shown with TPA or 4a-phorbol (100 nM) or Ro31-8220 (1 uM). 
Choline- and ethanolamine-metabolite release to the extracellular 
medium was assayed as described. Results are means from at least 
three separate wells of cells with radioactivity counted in duplicate 
and are ± S.E.M. 
39 
13000 rpm to pellet any cell fragments and duplicate aliquots of the 
supernatant were removed for scintillation counting to follow the 
phorbol ester-stimulated release of radiolabelled lipid headgroup me-
tabolites [8,10], Results are expressed as the mean dpm/aliquot of 
supernatant and are ± the S.E.M. calculated from triplicate or quad-
ruplicate wells treated identically. Individual experiments were re-
peated at least twice to ensure similar trends. 
3. Results 
3.1. Phorbol ester-stimulated release of lipid headgroup 
metabolites 
We have shown previously [7,8,10] that TPA-treatment of 
Cho- and Eth-labelled C6 cells stimulates the release of phos-
pholipid headgroup metabolites to the extracellular medium 
and that the bulk of the radioactivity is radiolabelled Cho or 
Eth indicative of PLD activation. Such findings are confirmed 
in Fig. 1A where TPA at 100 n M markedly stimulates the 
release of Cho-metabolites from C6 cells : this release increases 
with time in an almost linear manner up to at least 3 h. 
Treatment of C6 cells with the inactive 4oc-phorbol had no 
such stimulatory effect, values for metabolite release being 
similar to basal samples treated with DMSO alone. The stim-
ulatory effect of TPA on Cho-metabolite release was almost 
completely inhibited by treatment of cells with 1 u M Ro31-
TIME (hours) 
(TPA, PMA) and 4oe-phorbol were from the Alexis Corporation (UK) 
Ltd. (Bingham, Notts., England). 
2.2. Incubation of C6 cells 
C6 glioma cells were grown in DMEM supplemented with 10% FBS 
in 25 cm2 flasks. Medium was changed every third day. Cells were 
passaged when just confluent by rinsing with Tris-buflered saline fol-
lowed by releasing with 1 X trypsin/EDTA for 2 min. The trypsin was 
inactivated by addition of fresh DMEM/10% FBS and cells were 
passaged at a ratio of 1:3 or 1:4 into 12- or 24-well plates for experi-
ments. When cells were about 70-80% confluent medium was removed 
and fresh DMEM/10% FBS containing 0.5 uCi radiolabelled choline 
or ethanolamine was added back to each well for 24 h since about 15-
20 h are needed for equilibration of choline and ethanolamine pools in 
C6 cells [10]. 
2.3. Stimulation of cells and release of lipid headgroup metabolites 
Labelling medium was removed from wells and cells were rinsed 
twice with DMEM/10% FBS at 37°C. Fresh DMEM/10% FBS (500 
ul/well in a 24-well plate) containing suitable concentrations of TPA 
or 4a-phorbol with Ro31-8220, rapamycin or PD98059 as appropriate 
were then added and 30 ul aliquots of medium were immediately 
withdrawn into Eppendorf tubes on ice at time zero and at hourly 
intervals thereafter. These aliquots of supernatant were centrifuged at 
TIME (hours) 
Fig. 2. Action of rapamycin and PD98059 on the TPA-stimulated 
release of: A, choline- and B, ethanolamine-metabolites to the ex-
tracellular medium from C6 glioma cells. Cells were treated as in 
the legend to Fig. 1. TPA was at 100 nM, rapamycin was at 100 
nM and PD98059 was at 50 uM. Results are means from at least 
three separate wells of cells with radioactivity counted in duplicate 
and are ± S.E.M. 
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8220 (Fig. 1A) added at the same time as TPA. Ro31-8220 
also effectively inhibited Cho-metabolite release at a 100 nM 
concentration. When added to labelled C6 cells in the absence 
of TPA 1 uM Ro31-8220 had no effect on Cho-metabolite 
release. 
C6 glioma cells also show a well-defined TPA-stimulated 
release of Eth-lipid headgroup metabolites (Fig. IB) which 
is not observed with 4oc-phorbol. This TPA-stimulated release 
of Eth-headgroup metabolites is also blocked by 1 u,M Ro31-
8220. In the absence of TPA 1 uM Ro31-8220 had no effect 
on Eth-metabolite release from C6 cells over a 3 h period. 
3.2. Effects of rapamycin and PD98059 
The results in Fig. 2A demonstrate clearly that the immuno-
suppressant, rapamycin, at a concentration of 100 nM had no 
inhibitory effect on the TPA-stimulated release of Cho-metab-
olites to the extracellular medium. Higher concentrations of 
rapamycin (1 uM) were also without effect. As shown in Fig. 
2B rapamycin also had no effect on the TPA-stimulated re-
lease of Eth-metabolites to the extracellular medium. Rapa-
mycin alone at 100 nM caused no change in the basal release 
of Cho- or Eth-lipid headgroup metabolites to the medium. 
The TPA-stimulated release of Cho- or Eth-lipid headgroup 
metabolites from C6 cells was also not inhibited by the 
MAPKK inhibitor PD98059, which blocks activation of 
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Fig. 3. Action of staurosporine (STA) at different concentrations on 
the TPA-stimulated release of: A, choline- and, B, ethanolamine-
metabolites to the extracellular medium from C6 cells. Cells were 
treated as in the legend to Fig. 1. Results are means from at least 
three separate wells of cells with radioactivity counted in duplicate 
and are ± S.E.M. 
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Fig. 4. Action of wortmannin (WM, 5 uM) on the TPA-stimulated 
release of: A, choline- and B, ethanolamine-metabolites to the ex-
tracellular medium from C6 cells. Cells were treated as in the legend 
to Fig. 1. Results are means from at least three separate wells of 
cells with radioactivity counted in duplicate and are ± S.E.M. 
MAPKAP kinase-lß. PD98059 was used at a concentration 
of 50 uM as reported [11]. At this concentration, in the ab-
sence of TPA, PD98059 alone had no effect on Cho- or Eth-
metabolite release. 
3.3. Ro31-8220 and staurosporine differ in their effects 
Staurosporine, the parent compound from which Ro31-
8220 is derived, was less effective in inhibiting TPA-stimulated 
Cho-metabolite release from C6 cells than Ro31-8220 (Fig. 
3A). At 1 uM staurosporine induced a slight inhibition of 
Cho-metabolite release but this was not so obvious at a con-
centration of 10 uM. Curiously, staurosporine was more ef-
fective at inhibiting TPA-stimulated Eth-metabolite release 
from C6 cells: concentrations of 1 uM and 10 uM produced 
about a 50% inhibition (Fig. 3B). 
3.4. Effect of the PI-3 kinase inhibitor, wortmannin 
Wortmannin, at a concentration of 5 uM, had no inhibitory 
effect on the TPA-stimulated release of Cho-metabolites from 
C6 cells (Fig. 4A) and had no influence used alone on basal 
Cho-metabolite release values. On the other hand, the same 
concentration of wortmannin almost completely inhibited 
TPA-stimulated Eth-metabolite release (Fig. 4B). In the ab-
sence of TPA 5 uM wortmannin alone had no effect on basal 
Eth-metabolite release values (Fig. 4B). 
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4. Discussion 
PKC, the only kinase activated by phorbol esters such as 
TPA, is a major regulator of PLD [12-15,27] which catalyses 
the stimulated turnover of PtdCho and PtdEth by both PKC-
dependent and PKC-independent routes [4,12,16,17,27]. It is 
not yet resolved whether PKC activates PLD directly or via 
other signalling molecules such as Rho and ARF [27]. In most 
cells activation of PLD via PKC results in the stimulated 
turnover of PtdCho but in C6 glioma cells and type 1 astro-
cytes in primary culture a stimulated turnover of ethanol-
amine-containing phosphoglycerides, including both diacyl 
and plasmalogenic forms, also occurs [8,10,12,18]. Release 
of Cho- and Eth-metabolites to the extracellular medium is 
a direct way to follow PKC-stimulated turnover of complex 
lipids via PLD and the bulk of the radioactivity released is 
Cho or Eth indicative of PLD activation [8,10]. Radiolabelled 
Eth released from cells in such experiments does not arise by 
the action of an extracellular phosphatase on PEth [18]. To 
observe radiolabelled lipid headgroup metabolite release most 
efficiently cold Cho or Eth has to be in the extracellular me-
dium [8,10,18] because released lipid headgroups are chan-
nelled back into cells for biosynthesis [19]. 
Here we show again that TPA, but not inactive 4a-phorbol, 
clearly stimulates the turnover of PtdCho and PtdEth in C6 
glioma cells as revealed by the almost linear increase in Cho-
and Eth-metabolites in the external medium over basal levels 
up to 3 h. The steady basal release of headgroup metabolites 
presumably represents the normal turnover of phospholipid 
headgroups and release of choline- and ethanolamine-metab-
olites for re-use [19]. The TPA-stimulated turnover of complex 
lipids is completely blocked by 100 nM Ro31-8220, a concen-
tration which is well below the 2.5-5 |xM level at which this 
inhibitor causes activation of the stress-activated protein kin-
ase JNK1 [20]. Until recently such findings with Ro31-8220 
would have indicated an involvement of PKC in PLD activa-
tion. However, the recent report of Alessi [6] that Ro31-8220 
is a good inhibitor of p70S6k and MAPKAP kinase-Iß in 
vitro, in addition to its inhibition of PKC, means that such 
conclusions cannot be drawn until the involvement of these 
other kinases has been examined. Alessi states [6] that rapa-
mycin is a specific inhibitor of p70S6k while PD98059 specifi-
cally blocks MAPKAP kinase-Iß activity by inhibiting activa-
tion of MAPKK-1 [11]. These two inhibitors can therefore be 
used to define the role of p70S6k and MAPKAP kinase-Iß in 
signalling pathways. Our results (Fig. 2) show that neither 
rapamycin nor PD98059 inhibit the TPA-stimulated release 
of Cho- and Eth-metabolites. This shows that p70S6k and 
MAPKAP kinase-Iß are not involved in signalling pathways 
downstream of PKC to PLD. PD98059 acts by preventing 
activation of MAPKK-1 by Raf so our findings suggest that 
MAPK also does not function between PKC and PLD. Ra-
pamycin and PD98059 alone had no effect on basal Cho- and 
Eth-lipid head group release from C6 cells indicating that 
these substances do not directly stimulate PLD, PC-PLC or 
other signalling molecules regulating pathways to PLD and 
PC-PLC. The concentrations of rapamycin used (100 nM, 
1 uM) are greatly in excess by 20 and 200 times respectively 
of the 5 nM concentration reported to completely inhibit 
p70S6k f r o m s e v e r a i different cell types [28,29]. PD98059 was 
used at 50 |0.M as reported for intact cells by Alessi et al. [Il] 
to inhibit MAPKK-1. We know from related work that 100 
nM rapamycin fully inhibits synthesis of PKC-e in C6 cells 
(Beale, G., unpublished results) and that 50 uM PD98059 
inhibits PKC-e synthesis in 3T6 fibroblasts (Watson, J., un-
published results). 
Ro31-8220, however, still fully inhibits Cho- and Eth-me-
tabolite release from C6 cells confirming our previous results 
with C6 cells [7,8] and results of others with neutrophils and 
fibroblasts [4,9]. The 100 nM concentration of Ro31-8220 
used is well below the IC50 value at which protein kinase A 
or calcium/calmodulin-dependent protein kinase are inhibited 
[2] and, as our findings above also exclude an involvement of 
p70S6k and MAPKAP kinase-Iß, this result with Ro31-8220 
indicates a role for PKC in phorbol ester-stimulated phospho-
lipid turnover, as previously believed [12,27]. The oc and ß 
subspecies of PKC, but not the 5-, £- or Ç-forms have been 
found to activate PLD in fibroblast membranes [21] while 
overexpression studies in fibroblasts have linked PKC-ßi to 
PLD activation [22]. A down-regulation approach in C6 cells 
also reveals a role for PKC-a in activating PLD [8]. 
The specific PI-3 kinase inhibitor, wortmannin, blocked the 
TPA-stimulated release of Eth-lipid metabolites but had no 
effect on the release of Cho-lipid metabolites (Fig. 4). This 
suggests that different PLD isoforms regulate the turnover 
of PtdCho and PtdEth in C6 cells. Both forms are regulated 
partly through PKC as shown by the common stimulatory 
effect of TPA and the action of Ro31-8220. The PtdEth-hy-
drolysing PLD isoform, additionally, is regulated through PI-
3 kinase. In C6 cells the PtdEth-specific PLC may have a 
specific requirement for PIP3 since such very polar lipids are 
needed for PLD activity [16,23]. Alternatively, there may be 
an as yet undefined link between PI-3 kinase and the PtdEth-
specific PLD perhaps involving tyrosine kinases and/or small 
GTP-binding proteins such as Ras and Rho [16]. In adipo-
cytes an insulin-activated PC-PLD has been identified down-
stream of PI-3 kinase [25]. Different isoforms of PLD co-exist 
in the same cell and have separate cytosolic and membrane 
localisations [12,24]. The differing effects of staurosporine 
(Fig. 3) on TPA-stimulated Cho- and Eth-metabolite release 
also support the view that separate PLD isoforms regulate the 
TPA-stimulated turnover of PtdCho and PtdEth in C6 cells. 
However, staurosporine effects are hard to interpret since this 
compound can directly activate PLD at high concentrations 
[26]. At 10 (J,M the slight inhibitory effect of staurosporine on 
TPA-stimulated Cho-metabolite release was reversed while 
this was not the case for TPA-stimulated Eth-metabolite re-
lease where inhibition increased. 
This study confirms that p70S6k, MAPK and MAPKAP 
kinase-Iß are not involved downstream of PKC in signalling 
to PLD and that Ro31-8220 blocks TPA-stimulated PtdCho 
and PtdEth turnover by inhibiting PKC. Results with wort-
mannin suggest that TPA-stimulated turnover of PtdCho and 
PtdEth in C6 glioma cells may be mediated through separate 
PLD isoforms. Both isoforms are regulated through PKC but 
the PtdEth-PLD is regulated additionally via PI-3 kinase. 
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